Healthcare costs and utilization for privately insured patients treated for non-infectious uveitis in the USA

Chu, David S; Johnson, Scott J; Mallya, Usha G; Davis, Matthew R; Sorg, Rachael A; Duh, Mei Sheng

doi:10.1186/1869-5760-3-64

Journal of Ophthalmic Inflammation and Infection

Table 2 Baseline ophthalmologic comorbidities, utilization, costs, and prior therapy for patients with non-infectious uveitis by treatment group

From: Healthcare costs and utilization for privately insured patients treated for non-infectious uveitis in the USA

	CTS patients ^a (N = 4,568)	IMS patients ^b (N = 5,466)	BIO patients (N = 1,694)
Patient months	27,408	32,796	10,164
Baseline monthly ophthalmologic comorbidities, mean (std)
Glaucoma	0.041 (0.15)	0.045 (0.16)	0.028 (0.13)^a,b
Cataract	0.022 (0.09)	0.024 (0.10)	0.016 (0.08)^a,b
Cystoid macular degeneration	0.004 (0.03)	0.008 (0.06)^a	0.008 (0.07)^a
Retinal detachments	0.006 (0.05)	0.007 (0.06)	0.005 (0.06)^a,b
Visual disturbances	0.005 (0.04)	0.007 (0.05)^a	0.006 (0.05)
Blindness	0.001 (0.02)	0.002 (0.02)^a	0.002 (0.02)^a
Other visual complications	0.012 (0.06)	0.024 (0.11)^a	0.019 (0.11) ^b
Baseline Charlson Comorbidity Index (CCI), mean (std)	0.482 (1.06)	0.730 (1.29)^a	0.802 (1.15)^a,b
Baseline monthly comorbidities, mean (std)
Crohn's disease	0.009 (0.10)	0.024 (0.22)^a	0.086 (0.43)^a,b
Rheumatoid arthritis	0.010 (0.09)	0.036 (0.18)^a	0.125 (0.33)^a,b
Psoriasis	0.005 (0.10)	0.017 (0.18)^a	0.054 (0.31)^a,b
Ankylosing spondylitis	0.005 (0.06)	0.013 (0.10)^a	0.095 (0.23)^a,b
Baseline monthly total healthcare costs, mean [median] (std) (US$)	935 [279] (2,840)	1,738 [492] (5,763)^a	1,439 [597] (3,171)^a,b
Medical services	735 [134] (2,741)	1,497 [288] (5,668)^a	1,204 [375] (3,039)^a,b
Inpatient stay (IP)	294 [0] (2,177)	692 [0] (4,816)^a	408 [0] (2,233)^a
Emergency room (ER)	18 [0] (119)	24 [0] (142)^a	26 [0] (113)^a,b
Office/outpatient (OP)	423 [123] (1,041)	782 [263] (1,787)^a	771 [337] (1,528)^a,b
Pharmacy services	200 [66] (453)	241 [87] (483)^a	234 [104] (485)^a,b
Corticosteroids	0 [0] (0)	3 [0] (9)^a	3 [0] (11)^a
Immunosuppressants	9 [0] (82)	0 [0] (0)^a	20 [0] (104)^a,b
Biologics	24 [0] (193)	48 [0] (271)^a	0 [0] (0)^a,b
Baseline monthly total healthcare resource utilization
Inpatient stay (IP)
Number of patients, N (%)	64 (1.4%)	114 (2.1%)^a	39 (2.3%)^a
Number of stays/patient, mean (SD)	0.029 (0.19)	0.044 (0.22)^a	0.045 (0.19)^a
Number of days/ hospitalized patient, mean (SD)	3.88 (8.05)	4.133 (5.76)	3.908 (4.03)^a
Emergency room (ER)
Number of patients, N (%)	89 (2.0%)	132 (2.4%)^a	46 (2.7%)^a
Number of visits/patient, mean (SD)	0.028 (0.10)	0.035 (0.11)^a	0.042 (0.12)^a
Office/outpatient (OP)
Number of patients, N (%)	722 (15.8%)	900 (16.5%)^a	281 (16.6%)^a,b
Number of visits/patient, mean (std)	1.426 (1.48)	2.172 (1.82 )^a	2.372 (1.82)^a,b
Baseline treatment characteristics (over the 6 month period), N (%)
Baseline any corticosteroid use	--	3,784 (69.2%)^a	1,217 (71.8%)^a,b
Baseline any immunosuppressant use	280 (6.1%)	--	652 (38.5%)^a,b
Baseline any biologic use	112 (2.5%)	313 (5.7%)^a	--

CTS, corticosteroids; IMS, immunosuppressive therapy; BIO, biologics. Chi-square tests were used to test differences in categorical variables. Wilcoxon tests were used to test differences in continuous variables. ^a,bData with superscripted letter(s) indicate a significant difference (P < 0.05) from the uveitis subtype represented by that letter.

Back to article page